$24.77▲ 0.08 (0.32%)
Real-time prices · US Markets90% of 20 covering analysts have a positive rating.
currently unprofitable (-85% margin).
Quality
0.2
Health
5.9
Growth
6.5
Valuation
6.9
Sentiment
8.6
Analyst Target
$53.35
▲ +115.4% from current
Price Chart
Latest News
- Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
- Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial
- Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-1945.8×
next 12 months est.
Market Cap
$2.4B
market capitalization
Div Yield
—
dividend yield
Profit Margin
-85.4%
net profit margin
Gross Margin
-27.6%
revenue minus COGS
ROE
-608.5%
return on equity
Beta
0.25
vs S&P 500
Price / Book
—
P/B ratio
52-Week Range
$18 — $42
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
Is RARE a good stock to buy right now?
Ultragenyx Pharmaceutical Inc.'s Q·Score is 5.2/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. 90% of 20 covering analysts have a positive rating. Key area to monitor: currently unprofitable (-85% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for RARE?
The consensus price target for RARE is $53.35, based on ratings from 20 Wall Street analysts. This is 115.4% above the current price of $24.77. Price targets are forward-looking estimates and not guarantees of future performance.
Is RARE overvalued or undervalued?
Ultragenyx Pharmaceutical Inc. (RARE) scores in line with sector averages on valuation metrics. The consensus analyst price target of $53.35 is 115% above the current price.
When does Ultragenyx Pharmaceutical Inc. report its next earnings?
Ultragenyx Pharmaceutical Inc. is scheduled to report earnings in 2 days, on May 5, 2026.
What is Ultragenyx Pharmaceutical Inc.'s profit margin?
Ultragenyx Pharmaceutical Inc. has a net profit margin of -85.4%, indicating the company is currently operating at a net loss. Its gross margin stands at -27.6%, reflecting a more cost-intensive business model.
Is Ultragenyx Pharmaceutical Inc.'s revenue growing?
Ultragenyx Pharmaceutical Inc. is reporting strong year-over-year growth of 25.9%.